Silencing of lncRNA PART1 inhibits proliferation, invasion and migration of breast cancer cells and promotes the efficacy of cisplatin in breast cancer cells

Abstract

LncRNAs have proved to be related to the progression of multiple cancers. The present study aimed to investigate the effect of PART1 on the proliferation, invasion and migration of breast cancer cells and the efficacy of cisplatin in these cells. The expression of lncRNA PART1 in tissues and cells were detected by RT-qPCR analysis which was also used to verify the transfection effects. The cell proliferation, invasion and migration of breast cancer cells were respectively analyzed by CCK-8 assay, transwell assay and wound healing assay. The cell apoptosis was determined by flow cytometry analysis. The detection of CDK2, cyclinE1, P21, MMP3, MMP10, MMP13, Bcl2, Bax, cleaved caspase-3, caspase-3, MDP1, MRP1, GST-π and ABCB1 expression was performed by Western blot analysis. The results revealed that PART1 was increased in breast cancer tissues and cells, silencing of PART1 significantly inhibited cell proliferation, invasion and migration by regulating the expression of relative proteins. In addition, silencing of PART1 obviously improved the sensitivity of breast cancer cells to cisplatin, promoted cell apoptosis, and decreased the expression of breast cancer resistance proteins. In conclusion, silencing of PART1 inhibited proliferation, invasion and migration of breast cancer cells and promoted the efficacy of cisplatin in these cells. Therefore, PART1 may be considered as a novel therapeutic target in breast cancer.

WITHDRAWN: LncRNA RP3-326I13.1 Promoted Cisplatin Resistance of Lung Adenocarcinoma by Collaborating RNA Binding Protein HSP90B and Upregulating Downstream Molecule MMP13 

“…We further veri ed that MMP13, CP, ICAM1, CDK18 were consistently expressed in the RP3-326I13.1 group by both interference and overexpression, and further indicating that these four mRNA molecules were key mRNAs downstream of RP3-326I13.1. MMP13 had been reported to be involved in the mechanism of cisplatin resistance in some tumors [20][21][22]. Further studies shown that MMP13 could enhance the ability of lung adenocarcinoma cell lines to add value and cisplatin resistance.…”

“…The role of MMP13 in cisplatin in lung adenocarcinoma was further investigated considering the literatures [20][21][22]. Compared to 0 h, OD450nm absorbance values were signi cantly increased in each group at 24 h (P < 0.001, P < 0.001 and P < 0.001) and 48 h (P < 0.001, P < 0.001, P < 0.001 and P < 0.001).…”